Sorafenib prevents the proliferation and induces the apoptosis of liver cancer cells by regulating autophagy and hypoxia-inducible factor-1

Sorafenib has been approved as a systemic drug for advanced liver cancer; however, the underlying mechanisms remain unclear. The present study aimed to investigate the effects of sorafenib on the proliferation, autophagy and apoptosis of HepG2 cells under hypoxia. Briefly, reverse transcription-quan...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Qingzhuang, Gao, Lianghui, Huang, Xiaolong, Weng, Jie, Chen, Youke, Lin, Shibu, Yin, Qiushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311259/
https://www.ncbi.nlm.nih.gov/pubmed/34345262
http://dx.doi.org/10.3892/etm.2021.10412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311259/
https://www.ncbi.nlm.nih.gov/pubmed/34345262
http://dx.doi.org/10.3892/etm.2021.10412

Ejemplares similares